A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria

GU Höglinger, CH Adler, D Berg, C Klein… - The Lancet …, 2024‏ - thelancet.com
With the hope that disease-modifying treatments could target the molecular basis of
Parkinson's disease, even before the onset of symptoms, we propose a biologically based …

Genetics and pathogenesis of Parkinson's syndrome

H Ye, LA Robak, M Yu, M Cykowski… - Annual Review of …, 2023‏ - annualreviews.org
Parkinson's disease (PD) is clinically, pathologically, and genetically heterogeneous,
resisting distillation to a single, cohesive disorder. Instead, each affected individual develops …

Inflammation and immune dysfunction in Parkinson disease

MG Tansey, RL Wallings, MC Houser… - Nature Reviews …, 2022‏ - nature.com
Parkinson disease (PD) is a progressive neurodegenerative disease that affects peripheral
organs as well as the central nervous system and involves a fundamental role of …

Challenges in the diagnosis of Parkinson's disease

E Tolosa, A Garrido, SW Scholz, W Poewe - The Lancet Neurology, 2021‏ - thelancet.com
Parkinson's disease is the second most common neurodegenerative disease and its
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …

Parkinson's disease

BR Bloem, MS Okun, C Klein - The Lancet, 2021‏ - thelancet.com
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

Role of dopamine in the pathophysiology of Parkinson's disease

ZD Zhou, LX Yi, DQ Wang, TM Lim, EK Tan - Translational …, 2023‏ - Springer
A pathological feature of Parkinson's disease (PD) is the progressive loss of dopaminergic
neurons and decreased dopamine (DA) content in the substantia nigra pars compacta in PD …

Neuropathology and molecular diagnosis of Synucleinopathies

S Koga, H Sekiya, N Kondru, OA Ross… - Molecular …, 2021‏ - Springer
Synucleinopathies are clinically and pathologically heterogeneous disorders characterized
by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies …

Parkinson's disease: etiopathogenesis and treatment

J Jankovic, EK Tan - Journal of Neurology, Neurosurgery & Psychiatry, 2020‏ - jnnp.bmj.com
The concept of 'idiopathic'Parkinson's disease (PD) as a single entity has been challenged
with the identification of several clinical subtypes, pathogenic genes and putative causative …

Progress towards therapies for disease modification in Parkinson's disease

N Vijiaratnam, T Simuni, O Bandmann… - The Lancet …, 2021‏ - thelancet.com
The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Ferroptosis in Parkinson's disease: molecular mechanisms and therapeutic potential

X Ding, L Gao, Z Han, S Eleuteri, W Shi, Y Shen… - Ageing research …, 2023‏ - Elsevier
Parkinson's Disease (PD) is characterized by the progressive loss of dopaminergic neurons
in the substantia nigra (SN), leading to motor and non-motor symptoms. While the exact …